Home > Search Results: Gomez-Veiga, Francisco
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
10 p, 1013.3 KB Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice : ANALUTS study / Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ; Gómez-Caamaño, Antonio (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ; de Celis, Raúl Poza (Hospital Txagorritxu HUA) ; Gómez-Veiga, Francisco (Complejo Hospitalario Universitario de A Coruña) ; Ciria, Juan P. (Hospital de Donostia (Sant Sebastià, País Basc)) ; Calleja, Jesús (Hospital Clínico Universitario Valladolid) ; Extramiana, Javier (Hospital Txagorritxu HUA) ; Pérez-Sampietro, Maria (Ipsen Pharma) ; Perrot, Valerie (Ipsen Pharma) ; Angulo, Javier C. (Universidad Europea de Madrid) ; Universitat Autònoma de Barcelona
To estimate the prevalence of lower urinary tract symptoms (LUTS) in patients with prostate cancer scheduled to receive LHRH analogs, and to assess the effectiveness of LHRH analogs on LUTS in patients presenting moderate/severe symptoms. [...]
2022 - 10.1002/nau.25031
Neurourology and Urodynamics, Vol. 41 (september 2022) , p. 1824-1833  
Detailed record - Creative Commons
2.
11 p, 832.5 KB Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer : Data from the Prostate Cancer Registry / Bjartell, Anders (Lund University. Department of Translational Medicine, Medical Faculty) ; Lumen, Nicolaas (Universitair Ziekenhuis Gent) ; Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Paiss, Thomas (Urologie team Ulm, Ulm, Germany) ; Gomez-Veiga, Francisco (Instituto de Investigación Biomédica de Salamanca) ; Birtle, Alison (Royal Preston Hospital) ; Kramer, Gero (Medical University of Vienna. Department of Urology) ; Kalinka, Ewa (Polish Mother's Memorial Hospital, Research Institute. Clinic of Oncology) ; Spaëth, Dominique (Centre d'Oncologie de Gentilly, Nancy, France) ; Feyerabend, Susan (Studienpraxis Urologie, Nürtingen, Germany) ; Matveev, Vsevolod (N.N. Blokhin National Cancer Research Center) ; Lefresne, Florence (Janssen Pharmaceutica N.V.. EMEA Oncology) ; Lukac, Martin (Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V) ; Wapenaar, Robert (Janssen-Cilag B.V., Breda, The Netherlands) ; Costa, Luis (Universidade de Lisboa. Oncology Division, Faculdade de Medicina, Hospital de Santa Maria, Instituto de Medicina Molecular) ; Chowdhury, Simon (Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute) ; Universitat Autònoma de Barcelona
Despite standard-of-care androgen-deprivation therapy and an increasing number of treatment options, the mortality rate for prostate cancer remains high. Progress to metastatic castration-resistant prostate cancer (mCRPC) necessitates additional treatments. [...]
2021 - 10.1007/s11523-021-00807-4
Targeted Oncology, Vol. 16 (april 2021) , p. 357-367  
Detailed record - Creative Commons
3.
15 p, 623.6 KB Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer : The Prostate Cancer Registry / Chowdhury, Simon (Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute) ; Bjartell, Anders (Skåne University Hospital (Suècia)) ; Lumen, Nicolaas (Universitair Ziekenhuis Gent) ; Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Paiss, Thomas (Urologie Team Ulm, Ulm, Germany) ; Gomez-Veiga, Francisco (Instituto de Investigación Biomédica de Salamanca) ; Birtle, Alison (Royal Preston Hospital) ; Kramer, Gero (Medical University of Vienna. Department of Urology) ; Kalinka, Ewa (Polish Mother's Memorial Hospital-Research Institute. Clinic of Oncology) ; Spaëth, Dominique (Centre d'Oncologie de Gentilly, Nancy, France) ; Feyerabend, Susan (Studienpraxis Urologie, Nürtingen, Germany) ; Matveev, Vsevolod (N.N. Blokhin National Cancer Research Center) ; Lefresne, Florence (EMEA Oncology, Janssen Pharmaceutica N.V., Beerse, Belgium) ; Lukac, Martin (Parexel International Czech Republic s.r.o, on behalf of Janssen Pharmaceutica N.V) ; Wapenaar, Robert (Janssen-Cilag B.V., Breda, the Netherlands) ; Costa, Luis (Universidade de Lisboa. Oncology Division, Hospital de Santa Maria, Instituto de Medicina Molecular, Faculdade de Medicina)
Metastatic prostate cancer has a 30% 5-year survival rate despite recent therapeutic advances. There is a need to improve the clinical understanding and treatment of this disease, particularly in the real-world setting and among patients who are under-represented in clinical trials. [...]
2020 - 10.1007/s11523-020-00720-2
Targeted Oncology, Vol. 15 (june 2020) , p. 301-315  
Detailed record - Creative Commons

See also: similar author names
3 Gómez-Veiga, Francisco
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with